A Clinical Study of Tobradex AF

The purpose of this study is to determine the amount of study medication that moves from the front of the eye into the fluid at the front of the inside of the eye.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cataract Eye Diseases Lens Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Pittsburgh

Pittsburgh, Pennsylvania, 15122, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients requiring cataract surgery

Exclusion criteria

Age related

Treatment and study plan

Tobradex AF

Drug

Primary outcomes

Concentration of dexamethasone in aqueous humor following a single topical ocular administration

Time frame: Periodic

Secondary outcomes

Changes in external and internal ocular structures, intraocular pressure, vision and other side effects

Time frame: Periodic

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start: 2006
Primary completion: 2007
First posted: May 14, 2007
Registry last updated: Jul 29, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed